
Here are Monday's biggest analyst calls: Apple, Tesla, Amazon, Nike, Microsoft, Walmart & more
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
27 minutes ago
- Business Insider
‘It's Only Just Begun,' Says Andres Sheppard About Tesla Stock
Tesla (NASDAQ:TSLA) stock is steering into the future – quite literally. On June 22, the company officially launched its much-anticipated robotaxi service in Austin. Tesla began using Model Y vehicles equipped with autonomous driving technology to transport select invite-only passengers around predefined neighborhoods at a playful flat fee of $4.20 per ride. For now, however, each vehicle still includes a safety monitor seated in the front passenger seat, providing an additional layer of supervision and reassurance during these autonomous trips. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. It wasn't long before Tesla took its next leap forward: on June 27, the company completed its first fully autonomous vehicle delivery. Imagine a Model Y quietly departing Tesla's Gigafactory, cruising effortlessly through Austin's streets, and parking itself in the customer's driveway without a single human intervention – that's exactly what happened. Furthermore, the company announced plans last week to ramp up its robotaxi operation in Austin by adding more vehicles and expanding service coverage. As the system matures and local regulations allow, Tesla aims to phase out the in-car safety monitors altogether, ushering in a truly driverless passenger experience. Looking further ahead, Tesla is already sketching out the next generation of autonomous ride-sharing. In 2026, the automaker plans to roll out its futuristic Cybercab – a purpose-built, fully autonomous vehicle without a steering wheel or pedals. Cantor analyst Andres Sheppard sees Tesla's latest moves as another powerful signal of the company's strategic edge in the rapidly evolving autonomous vehicle landscape. According to Sheppard, Tesla's focus on expanding its robotaxi services marks a critical step toward solidifying its role as a frontrunner in the competitive ride-sharing market. 'We expect Robotaxi expansion into the Bay Area (in 3Q), followed by Arizona, Nevada and possibly Florida (in 4Q25/2026E), subject to regulatory approvals… Overall, we continue to see Tesla's Robotaxi segment as a software-as-a-service, high-margin model, and we expect TSLA to have the ability to rapidly scale following commercialization. We expect TSLA will capture a leading market share in these industries,' Sheppard opined. To this end, Sheppard rates TSLA shares an Overweight (i.e., Buy) along with a $355 price target. (To watch Sheppard's track record, click here) What does the rest of the Street think? Looking at the consensus breakdown, opinions from other analysts are more spread out. 14 Buys, 15 Holds and 8 Sells add up to a Hold (i.e. Neutral) consensus rating. In addition, the $310.65 average price target indicates ~5% downside from current levels. (See TSLA stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.


Business Insider
27 minutes ago
- Business Insider
Tesla Faces $5,900 Robot Challenger as Unitree Unveils R1 Humanoid
Chinese robotics company Unitree has revealed its new humanoid robot, the R1, with a starting price of $5,900. The company introduced the robot at the World AI Conference in Shanghai last week. The R1 drew public attention for its agility, including cartwheels and balance moves, demonstrated in live videos and online clips. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The R1 stands 4 feet tall and weighs 55 pounds. It includes 26 joints for multi-axis mobility and features voice and image recognition tools. Unitree states that the robot utilizes an 8-core chip with an integrated GPU. The device supports Wi-Fi 6 and Bluetooth 5.2 and includes a removable battery with a runtime of around one hour. The launch adds pressure to other companies in the humanoid robotics space, including Tesla (TSLA). Tesla has yet to ship its Optimus robot and has not confirmed a production date, although Elon Musk projects producing 100,000 robots every month by 2030. Musk has also estimated that Optimus will cost at least $20,000. That is more than three times the R1's announced price. The R1's hardware shows a focus on motion over task performance. It does not include usable hands or physical manipulation tools. Analysts note that it is designed for testing and software development, rather than for home or factory use. Unitree has not provided a delivery timeline, but states that the robot is still in development. The company expects to use third-party dealers for global distribution. Previous Unitree robots have carried higher price tags. The G1 humanoid started at $16,000, while the H1 model reached a price of $90,000. The company says it wants to lower cost barriers for developers and early adopters. A Growing Industry The humanoid robotics space has drawn rising interest from investors. Boston Dynamics, owned by Hyundai Motor Company (HYMLF), has developed its Atlas robot for research use, but its price exceeds $100,000. Other companies working in the field include Agility Robotics, Apptronik, and Sanctuary AI, all of which are focused on enterprise deployment. The R1 launch aligns with government targets in China, where robotics is a national priority under industrial policy plans. Unitree has stated that it aims to integrate humanoid robots into homes and offices in the long term. For now, the R1 adds a new price benchmark in a market still early in commercial adoption. We used TipRanks' Comparison Tool to analyze Hyundai Motor Company (HYMLF) and Tesla (TSLA), both mentioned in the article. This gives you a broader view of how the two stocks compare across key metrics.


Business Insider
27 minutes ago
- Business Insider
What's Ahead for UnitedHealth (UNH) as Stock Drops 44% YTD?
UnitedHealth Group (UNH), the largest healthcare provider, is now one of the worst-hit stocks of 2025. Down 44% year-to-date, UNH stock was dragged down by rising costs in its Medicare Advantage business, a surprise CEO exit, and intensifying federal scrutiny into its billing practices. Currently, investors are looking for updates on the company's progress on the legal and financial front at the Q2 earnings, due July 29. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. What Went Wrong? The selloff in UNH stock began in April when UnitedHealth missed earnings and slashed its full-year guidance. This was followed by the resignation of CEO Andrew Witty in May. Also, last week, the company confirmed it is under both criminal and civil investigations by the Department of Justice. The probe centers on alleged overbilling in its Medicare Advantage program, specifically whether patient diagnoses were inflated to boost government reimbursements. Analysts Are Not That Bearish Despite the turmoil, Wall Street sentiment is mixed but not entirely bearish. Bernstein even named UNH a 'Top Pick,' citing its discounted valuation and long-term earnings potential. Further, the firm expects a doubling of EPS by 2029, driven by sector recovery and company-specific margin recovery. Others are more cautious. Wells Fargo and Truist Financial recently lowered their price targets, citing weak investor sentiment and concerns around Optum Health, UnitedHealth's services arm. All Eyes Are on UNH's Q2 Results Currently, analysts anticipate that Q2 earnings will fall to $4.48 from $6.80 a year ago. Meanwhile, revenue is expected to grow 12.8% to $111.50 billion. The bottom-line drop reflects higher-than-expected medical costs, especially in Medicare Advantage, which have hurt the company's margins. More than the Q2 numbers, investors are focused on CEO Stephen Hemsley offering a roadmap for recovery, including updated 2025 guidance and early signals for 2026. A full-year EPS outlook of below $18 could result in investors losing more confidence and trigger further selling. Is UNH a Good Buy Right Now? Turning to Wall Street, UNH stock has a Moderate Buy consensus rating based on 18 Buys, five Holds, and one Sell assigned in the last three months. At $348.12, the average UnitedHealth stock price target implies a 24.11% upside potential.